Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Kane Biotech

OTCPK:KNBI.F
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KNBI.F
OTCPK
CA$15M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. The last earnings update was 143 days ago. More info.


Add to Portfolio Compare Print
  • Kane Biotech has significant price volatility in the past 3 months.
KNBI.F Share Price and Events
7 Day Returns
-3.3%
OTCPK:KNBI.F
2.5%
US Biotechs
-2%
US Market
1 Year Returns
70.9%
OTCPK:KNBI.F
-0.9%
US Biotechs
-15.1%
US Market
KNBI.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kane Biotech (KNBI.F) -3.3% -39.8% -13.3% 70.9% - -46.1%
US Biotechs 2.5% -8.3% -4.1% -0.9% 10.9% -11.6%
US Market -2% -19.7% -23.2% -15.1% 3.7% 14.4%
1 Year Return vs Industry and Market
  • KNBI.F outperformed the Biotechs industry which returned -0.9% over the past year.
  • KNBI.F outperformed the Market in United States of America which returned -15.1% over the past year.
Price Volatility
KNBI.F
Industry
5yr Volatility vs Market

KNBI.F Value

 Is Kane Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Kane Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Kane Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Kane Biotech. This is due to cash flow or dividend data being unavailable. The share price is $0.0906.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kane Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kane Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:KNBI.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CAD CA$-0.01
TSXV:KNE Share Price ** TSXV (2020-04-03) in CAD CA$0.14
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.85x
United States of America Market PE Ratio Median Figure of 2,947 Publicly-Listed Companies 12.4x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kane Biotech.

OTCPK:KNBI.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:KNE Share Price ÷ EPS (both in CAD)

= 0.14 ÷ -0.01

-21.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kane Biotech is loss making, we can't compare its value to the US Biotechs industry average.
  • Kane Biotech is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Kane Biotech's expected growth come at a high price?
Raw Data
OTCPK:KNBI.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -21.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.81x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.89x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kane Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kane Biotech's assets?
Raw Data
OTCPK:KNBI.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CAD CA$-0.01
TSXV:KNE Share Price * TSXV (2020-04-03) in CAD CA$0.14
United States of America Biotechs Industry PB Ratio Median Figure of 430 Publicly-Listed Biotechs Companies 2.48x
United States of America Market PB Ratio Median Figure of 5,144 Publicly-Listed Companies 1.2x
OTCPK:KNBI.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:KNE Share Price ÷ Book Value per Share (both in CAD)

= 0.14 ÷ -0.01

-23.23x

* Primary Listing of Kane Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kane Biotech has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at our analysis of KNBI.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Kane Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kane Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

KNBI.F Future Performance

 How is Kane Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kane Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kane Biotech expected to grow at an attractive rate?
  • Unable to compare Kane Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Kane Biotech's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Kane Biotech's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:KNBI.F Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 17.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:KNBI.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:KNBI.F Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-09-30 1 -1 -1
2019-06-30 1 0 -1
2019-03-31 1 -3 -3
2018-12-31 1 -3 -3
2018-09-30 0 -3 -4
2018-06-30 0 -3 -4
2018-03-31 0 -3 -4
2017-12-31 0 -2 -3
2017-09-30 1 -2 -2
2017-06-30 1 -2 -2
2017-03-31 1 -2 -2
2016-12-31 0 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Kane Biotech is high growth as no earnings estimate data is available.
  • Unable to determine if Kane Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:KNBI.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Kane Biotech Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KNBI.F Past Financials Data
Date (Data in CAD Millions) EPS *
2019-09-30 -0.01
2019-06-30 -0.01
2019-03-31 -0.04
2018-12-31 -0.04
2018-09-30 -0.05
2018-06-30 -0.05
2018-03-31 -0.06
2017-12-31 -0.06
2017-09-30 -0.05
2017-06-30 -0.05
2017-03-31 -0.05
2016-12-31 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kane Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of KNBI.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Kane Biotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Kane Biotech's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Kane Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kane Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

KNBI.F Past Performance

  How has Kane Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kane Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kane Biotech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Kane Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Kane Biotech's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Kane Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kane Biotech Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KNBI.F Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1.30 -0.51 2.01 0.91
2019-06-30 1.13 -0.68 2.09 0.85
2019-03-31 1.02 -3.05 2.00 0.67
2018-12-31 0.51 -3.26 2.03 0.70
2018-09-30 -0.20 -4.06 2.24 0.78
2018-06-30 -0.25 -3.93 2.18 0.82
2018-03-31 -0.25 -4.04 2.28 0.82
2017-12-31 0.42 -3.40 2.40 0.79
2017-09-30 1.03 -2.40 2.51 0.67
2017-06-30 1.16 -2.14 2.27 0.62
2017-03-31 1.06 -2.21 2.33 0.70
2016-12-31 0.38 -2.55 2.12 0.57
2016-09-30 0.33 -2.53 2.09 0.53
2016-06-30 0.15 -2.32 1.97 0.40
2016-03-31 0.18 -1.80 1.60 0.25
2015-12-31 0.10 -1.71 1.46 0.27
2015-09-30 0.11 -1.69 1.32 0.26
2015-06-30 0.11 -1.62 1.19 0.34
2015-03-31 0.07 -1.80 1.05 0.38
2014-12-31 0.04 -1.61 0.86 0.37
2014-09-30 0.02 -1.29 0.83 0.38
2014-06-30 -1.27 0.84 0.35
2014-03-31 -1.09 0.86 0.33
2013-12-31 -1.45 1.16 0.39
2013-09-30 -1.74 1.22 0.38
2013-06-30 -1.80 1.21 0.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Kane Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Kane Biotech has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Kane Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Kane Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kane Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

KNBI.F Health

 How is Kane Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kane Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kane Biotech's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Kane Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kane Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Kane Biotech has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kane Biotech Company Filings, last reported 6 months ago.

OTCPK:KNBI.F Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -0.49 1.08 0.34
2019-06-30 0.05 1.39 1.33
2019-03-31 -1.63 1.57 0.12
2018-12-31 -0.98 1.10 0.08
2018-09-30 0.27 0.50 0.12
2018-06-30 1.20 0.00 0.34
2018-03-31 1.89 0.00 1.24
2017-12-31 2.12 0.00 1.98
2017-09-30 3.59 0.00 2.53
2017-06-30 0.44 0.91 0.26
2017-03-31 1.15 0.49 0.58
2016-12-31 1.35 0.48 0.74
2016-09-30 1.97 0.47 1.38
2016-06-30 2.58 0.46 2.01
2016-03-31 0.28 0.71 0.26
2015-12-31 0.48 0.44 0.12
2015-09-30 0.53 0.50 0.22
2015-06-30 0.63 0.48 0.25
2015-03-31 0.95 0.46 0.56
2014-12-31 1.32 0.45 0.97
2014-09-30 0.57 0.43 0.22
2014-06-30 0.90 0.42 0.44
2014-03-31 1.38 0.41 0.80
2013-12-31 1.28 0.41 0.63
2013-09-30 1.33 0.00 0.37
2013-06-30 1.63 0.00 0.67
  • Kane Biotech has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Kane Biotech's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Kane Biotech has less than a year of cash runway based on current free cash flow.
  • Kane Biotech has less than a year of cash runway if free cash flow continues to grow at historical rates of 10% each year.
X
Financial health checks
We assess Kane Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kane Biotech has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

KNBI.F Dividends

 What is Kane Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kane Biotech dividends.
If you bought $2,000 of Kane Biotech shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kane Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kane Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:KNBI.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 66 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1938 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2.1%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kane Biotech has not reported any payouts.
  • Unable to verify if Kane Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kane Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kane Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Kane Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kane Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kane Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

KNBI.F Management

 What is the CEO of Kane Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marc Edwards
COMPENSATION CA$77,382
TENURE AS CEO 1.6 years
CEO Bio

Mr. Marc Edwards is the Founder and President of VetRx, a Montreal-based technology company specializing in daollection, cleansing, marketing and pharmaceutical compliance for the veterinary industry. He has been a Director at Kane Biotech Inc. since June 02, 2016 and also has been its President & Chief Executive Officer since September 10, 2018. Mr. Edwards holds Bachelor's degree in Finance from l'Université de Sherbrooke and an MBA from Concordia University.

CEO Compensation
  • Marc's compensation has increased whilst company is loss making.
  • Marc's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Kane Biotech management team in years:

1.5
Average Tenure
  • The average tenure for the Kane Biotech management team is less than 2 years, this suggests a new team.
Management Team

Marc Edwards

TITLE
President
COMPENSATION
CA$77K
TENURE
1.6 yrs

Ray Dupuis

TITLE
Chief Financial Officer
COMPENSATION
CA$154K
TENURE
2.6 yrs

Mark Ahrens-Townsend

TITLE
COMPENSATION
CA$244K
TENURE
1.6 yrs

Gordon Guay

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board
TENURE
1.4 yrs

Lori Christofalos

TITLE
Director of Quality & Compliance
TENURE
0.7 yrs

Tony Romeo

TITLE
Chief Scientific Advisor and Member of Scientific Advisory Board

Jean Gauvin

TITLE
Chief Veterinary Officer & Member of Scientific Advisory Board
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure of the Kane Biotech board of directors in years:

2.7
Average Tenure
  • The average tenure for the Kane Biotech board of directors is less than 3 years, this suggests a new board.
Board of Directors

Philip Renaud

TITLE
Chairman
COMPENSATION
CA$23K

Marc Edwards

TITLE
President
COMPENSATION
CA$77K
TENURE
3.8 yrs

Gordon Guay

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board
TENURE
1.6 yrs

Tony Romeo

TITLE
Chief Scientific Advisor and Member of Scientific Advisory Board

Jean Gauvin

TITLE
Chief Veterinary Officer & Member of Scientific Advisory Board
TENURE
0.2 yrs

Mark Nawacki

TITLE
Independent Director
COMPENSATION
CA$17K
AGE
50
TENURE
5.7 yrs

Rivka Gluck

TITLE
Chairman of Scientific Advisory Board & Director
COMPENSATION
CA$11K
TENURE
1.6 yrs

Dennis Cvitkovitch

TITLE
Member of Scientific Advisory Board

George Zhanel

TITLE
Member of Scientific Advisory Board
COMPENSATION
CA$3K

Jeffrey Kaplan

TITLE
Member of Scientific Advisory Board
TENURE
9.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Kane Biotech individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. Mar 20 Buy Marc Edwards Individual 03. Mar 20 03. Mar 20 160,000 $0.14 $22,180
27. Dec 19 Buy Marc Edwards Individual 20. Dec 19 20. Dec 19 357,142 $0.11 $37,978
27. Dec 19 Buy Ray Dupuis Individual 19. Dec 19 19. Dec 19 178,571 $0.11 $19,043
27. Dec 19 Buy Philip Renaud Individual 19. Dec 19 19. Dec 19 2,142,857 $0.11 $228,512
12. Oct 19 Sell Rashieda Gluck Individual 08. Oct 19 08. Oct 19 -9,500 $0.10 $-962
27. Sep 19 Sell Rashieda Gluck Individual 23. Sep 19 27. Sep 19 -80,500 $0.10 $-7,739
12. Aug 19 Buy Marc Edwards Individual 08. Aug 19 08. Aug 19 175,000 $0.11 $18,763
X
Management checks
We assess Kane Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kane Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

KNBI.F News

Simply Wall St News

KNBI.F Company Info

Description

Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.

Details
Name: Kane Biotech Inc.
KNBI.F
Exchange: OTCPK
Founded: 2001
CA$10,375,033
108,613,535
Website: http://www.kanebiotech.com
Address: Kane Biotech Inc.
162-196 Innovation Drive,
Winnipeg,
Manitoba, R3T 2N2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV KNE Common Voting Shares TSX Venture Exchange CA CAD 20. May 2003
OTCPK KNBI.F Common Voting Shares Pink Sheets LLC US USD 20. May 2003
Number of employees
Current staff
Staff numbers
0
Kane Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 00:19
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.